||This article may require cleanup to meet Wikipedia's quality standards. The specific problem is: MOS (June 2016) (Learn how and when to remove this template message)|
|Classification and external resources|
Hypogonadism is a medical term which describes a diminished functional activity of the gonads – the testes and ovaries in males and females, respectively – that may result in diminished sex hormone biosynthesis. In layman's terms, it is sometimes called "interrupted stage 1 puberty". Low androgen (e.g., testosterone) levels are referred to as hypoandrogenism and low estrogen (e.g., estradiol) as hypoestrogenism, and may occur as symptoms of hypogonadism in both sexes, but are generally only diagnosed in males and females respectively. Other hormones produced by the gonads which may be decreased by hypogonadism include progesterone, DHEA, anti-Müllerian hormone, activin, and inhibin. Spermatogenesis and ovulation in males and females, respectively, may be impaired by hypogonadism, which, depending on the degree of severity, may result in partial or complete infertility.
Deficiency of sex hormones can result in defective primary or secondary sexual development, or withdrawal effects (e.g., premature menopause) in adults. Defective egg or sperm development results in infertility. The term hypogonadism is usually applied to permanent rather than transient or reversible defects, and usually implies deficiency of reproductive hormones, with or without fertility defects. The term is less commonly used for infertility without hormone deficiency. There are many possible types of hypogonadism and several ways to categorize them. Hypogonadism is also categorized by endocrinologists by the level of the reproductive system that is defective. Physicians measure gonadotropins (LH and FSH) to distinguish primary from secondary hypogonadism. In primary hypogonadism the LH and/or FSH are usually elevated, meaning the problem is in the testicles, whereas in secondary hypogonadism, both are normal or low, suggesting the problem is in the brain.
- Hypogonadism resulting from defects of the gonads is traditionally referred to as primary hypogonadism. Examples include Klinefelter syndrome and Turner syndrome. Mumps is known to cause testicular failure, and in recent years has been immunized against in the US. A varicocele can reduce hormonal production as well.
- Hypogonadism resulting from hypothalamic or pituitary defects are termed secondary hypogonadism or central hypogonadism (referring to the central nervous system).
- An example of a hypogonadism resulting from the lack of hormone response is androgen insensitivity syndrome, where there are inadequate receptors to bind the testosterone, resulting in a female appearance despite XY chromosomes.
Primary or secondary
- Primary - defect is inherent within the gonad: e.g. Noonan syndrome, Turner syndrome (45X,0), Klinefelter syndrome (47XXY), XY females with SRY gene-immunity
- Secondary - defect lies outside of the gonad: e.g. Polycystic ovary syndrome, and Kallmann syndrome, also called hypogonadotropic hypogonadism. Hemochromatosis and diabetes mellitus can be causes of this as well.
Congenital vs. acquired
- Examples of congenital causes of hypogonadism, that is, causes that are present at birth:
- Examples of acquired causes of hypogonadism:
- Opioid Induced Androgen Deficiency (resulting from the prolonged use of opioid class drugs, e.g. codeine,Dihydrocodeine, morphine, oxycodone, methadone, fentanyl, hydromorphone, etc.)
- Anabolic steroid-induced hypogonadism (ASIH)
- Childhood mumps
- Children born to mothers who had ingested the endocrine disruptor diethylstilbestrol for potential miscarriage
- Traumatic brain injury, even in childhood
- In males, normal aging causes a decrease in androgens, which is sometimes called "male menopause" (also known by the coinage "manopause"), late-onset hypogonadism (LOH), and andropause or androgen decline in the aging male (ADAM), among other names.
- It is a symptom of Hereditary Hemochromatosis
Hormones vs. fertility
- Examples of hypogonadism that affect hormone production more than fertility are hypopituitarism and Kallmann syndrome; in both cases, fertility is reduced until hormones are replaced but can be achieved solely with hormone replacement.
- Examples of hypogonadism that affect fertility more than hormone production are Klinefelter syndrome and Kartagener syndrome.
Signs and symptoms
Women with hypogonadism will not begin menstruating and it may affect their height and breast development. Onset in women after puberty causes cessation of menstruation, lowered libido, loss of body hair and hot flashes. In boys it causes impaired muscle and beard development and reduced height. In men it can cause reduced body hair and beard, enlarged breasts, loss of muscle, and sexual difficulties. A brain tumor (central hypogonadism) may involve headaches, impaired vision, milky discharge from the breast and symptoms caused by other hormone problems.
The symptoms of hypogonadotrophic hypogonadism, a subtype of hypogonadism, include late, incomplete or lack of development at puberty, and sometimes short stature or the inability to smell; in females, a lack of breasts and menstrual periods, and in males a lack of sexual development, e.g., facial hair, penis and testes enlargement, deepening voice.
Low testosterone can be identified through a simple blood test performed by a laboratory, ordered by a physician. This test is typically ordered in the morning hours, when levels are highest, as levels can drop by as much as 13% during the day.
Normal total testosterone levels range from 240–950 ng/dL (nanograms per decilitre)
Treatment is often prescribed for total testosterone levels below 230 ng/dL. If the serum total testosterone level is between 230 and 350 ng/dL, repeating the measurement of total testosterone with sex hormone-binding globulin (SHBG) to calculate free testosterone or free testosterone by equilibrium dialysis may be helpful.
The standard range given is based off widely varying ages and, given that testosterone levels naturally decrease as humans age, age-group specific averages should be taken into consideration when discussing treatment between doctor and patient. In men, testosterone falls approximately 1 to 3 percent each year.
- Blood testing
A position statement by The Endocrine Society has expressed dissatisfaction with the manner in which most assays for TT (Total Testosterone) and FT (Free Testosterone) are currently performed. In particular, research has questioned the validity of commonly administered assays of FT by RIA. The FAI (Free Androgen Index) has been found to be the worst predictor of Free Testosterone.
Similar to men, the LH and FSH will be used, particularly in women who believe they are in menopause. These levels change during a woman's normal menstrual cycle, so the history of having ceased menstruation coupled with high levels aids the diagnosis of being menopausal. Commonly, the post-menopausal woman is not called hypogonadal if she is of typical menopausal age. Contrast with a young woman or teen, who would have hypogonadism rather than menopause. This is because hypogonadism is an abnormality, whereas menopause is a normal change in hormone levels.
Hypogonadism is often discovered during evaluation of delayed puberty, but ordinary delay, which eventually results in normal pubertal development, wherein reproductive function is termed constitutional delay. It may be discovered during an infertility evaluation in either men or women.
Male hypogonadism is most often treated with testosterone replacement therapy (TRT) in patients who are not trying to conceive. Adverse effects of testosterone replacement therapy include increased cardiovascular events (including strokes and heart attacks) and deaths. The Food and Drug Administration (FDA) stated in 2015 that neither the benefits nor the safety of testosterone have been established for low testosterone levels due to aging. The FDA has required that testosterone pharmaceutical labels include warning information about the possibility of an increased risk of heart attacks and stroke.
Commonly used testosterone replacement therapies include transdermal (through the skin) using a patch or gel, injections, or pellets. Oral testosterone is no longer used in the U.S. because it is broken down in the liver and rendered inactive; it also can cause severe liver damage. Like many hormonal therapies, changes take place over time. It may take as long as 2–3 months at optimum level to reduce the symptoms, particularly the wordfinding and cognitive dysfunction. Testosterone levels in the blood should be evaluated to ensure the increase is adequate. Levels between 400 and 700 ng/dL are considered to be appropriate mid-dose levels. Treatment usually starts with 200 mg intramuscular testosterone, repeated every 14 days.
While historically men with prostate cancer risk were warned against testosterone therapy, that has shown to be a myth.
Other side effects can include an elevation of the hematocrit to levels that require blood to be withdrawn (phlebotomy) to prevent complications from it being "too thick". Another is that a man may have some growth in the size of the breasts (gynecomastia), though this is relatively rare. Finally, some physicians worry that Obstructive Sleep Apnea may worsen with testosterone therapy, and should be monitored.
For both men and women, an alternative to testosterone replacement is Clomifene treatment which can stimulate the body to naturally increase hormone levels while avoiding infertility and other side effects as a consequence of direct hormone replacement therapy.
For men, Aquaviron injections are may be use full.
For women, estradiol and progesterone are replaced. Some types of fertility defects can be treated, others cannot. Some physicians will also give testosterone to women, mainly to increase libido.
- Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
- Delayed puberty and infertility
- GnRH and gonadotropins (FSH and LH)
- Gonads (testicles and ovaries)
- Hypergonadism (hyperandrogenism and hyperestrogenism)
- Hypergonadotropic hypogonadism
- Hypoandrogenism and hypoestrogenism
- Hypogonadotropic hypogonadism
- Hypothalamus, pituitary gland, and HPG axis
- Isolated hypogonadotropic hypogonadism
- Sex hormones (androgens and estrogens)
- MedlinePlus Encyclopedia Hypogonadotropic hypogonadism
- MedlinePlus Encyclopedia Hypogonadism
- Crawford, E. David; Barqawi, Al Baha; O'Donnell, Colin; Morgentaler, Abraham (2007). "The association of time of day and serum testosterone concentration in a large screening population". BJU International 100 (3): 509–13. doi:10.1111/j.1464-410X.2007.07022.x. PMID 17555474. Lay summary – UroToday (12 July 2007).
- MedlinePlus Encyclopedia Testosterone
- Nieschlag E, Swerdloff R, Behre HM, et al. (2006). "Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations". Journal of Andrology 27 (2): 135–7. doi:10.2164/jandrol.05047. PMID 16474020.
- School, Florence Comite, MD ; Foreword by Abraham Morgentaler, MD associate clinical professor of urology, Harvard Medical (2013). Keep it up : the power of precision medicine to conquer low T and revitalize your life. Rodale Books. p. 14. ISBN 978-1609611019.
- Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H (February 2007). "Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement". The Journal of Clinical Endocrinology and Metabolism 92 (2): 405–13. doi:10.1210/jc.2006-1864. PMID 17090633.
- Morris PD, Malkin CJ, Channer KS, Jones TH (August 2004). "A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men". European Journal of Endocrinology 151 (2): 241–9. doi:10.1530/eje.0.1510241. PMID 15296480.
- Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF, Hoover RN (January 2014). "Increased Risk of Non-fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men" (PDF). PLoS ONE 9 (1): e85805. doi:10.1371/journal.pone.0085805. PMC 3905977. PMID 24489673.
- Staff (3 March 2015). "Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke". FDA. Retrieved 5 March 2015.
- Tavernise, Sabrina (March 3, 2015). "Drugs Using Testosterone Will Label Heart Risks". New York Times. Retrieved March 19, 2015.
- Morgentaler (2006). "Testosterone and prostate cancer: an historical perspective on a modern myth". European Urology 50 (5): 935–9. doi:10.1016/j.eururo.2006.06.034. PMID 16875775.
- Matsumoto, A. M.; Sandblom, R. E.; Schoene, R. B.; Lee, K. A.; Giblin, E. C.; Pierson, D. J.; Bremner, W. J. (1985-06-01). "Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep". Clinical Endocrinology 22 (6): 713–721. ISSN 0300-0664. PMID 4017261.
- Chudnovsky, A.; Niederberger, C. S. (2007). "Gonadotropin Therapy for Infertile Men with Hypogonadotropic Hypogonadism". Journal of Andrology 28 (5): 644–6. doi:10.2164/jandrol.107.003400. PMID 17522414.
- Whitten, S; Nangia, A; Kolettis, P (2006). "Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate". Fertility and Sterility 86 (6): 1664–8. doi:10.1016/j.fertnstert.2006.05.042. PMID 17007848.